Researchers report that whole-body diffusion-weighted MRI (WB-DWI/MRI) can predict outcomes after neoadjuvant chemotherapy for advanced ovarian cancer, in work published in the British Journal of Cancer. The study evaluates how diffusion-weighted imaging data relate to treatment response and subsequent clinical endpoints. WB-DWI/MRI is a whole-body imaging approach that captures tumor and treatment-related changes across multiple sites rather than relying on a single-region assessment. By linking imaging measures to outcomes post-NACT, the findings point to a potential decision-support tool for tailoring subsequent therapy. For oncology teams, the clinical value will hinge on how consistently WB-DWI/MRI patterns forecast response and whether they can be integrated into routine imaging workflows without adding substantial operational burden.